The association between type 2 diabetes and anhedonic subtype of major depression in hypertensive individuals

Willame, Hadrien; Wacquier, Benjamin; Point, Camille; Dosogne, Marjorie; Faker, Mohammed Al; Loas, Gwenolé; Hein, Matthieu

doi:10.1111/jch.14411

Cited by 11 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from this study are consistent with prior work showing that even after controlling for overall depression severity, anhedonia is associated with a range of adverse outcomes that compound the burden of depression, including poorer treatment response (16-19), greater comorbidity (12,13), greater suicidality (11), and more persistent psychosocial and functional impairment (5). Furthermore, our data align with prior studies highlighting links between reward-related neural correlates of anhedonia -namely, the RewP -and greater depression morbidity (e.g., recurrence and suicidality; 31, 32).…”

Section: Discussionsupporting

confidence: 88%

“…Anhedonia is increasingly recognized as a predictor of poorer clinical and functional outcomes and is likely an important factor contributing to depression-related disease burden (10). Even after controlling for overall depressive symptom severity, more severe anhedonia uniquely predicts greater psychosocial and functional impairment (5), increased suicidal ideation (11), greater psychiatric (12) and medical (13) comorbidity, as well as increased caregiver stress (14). Anhedonia and its corollaries (e.g., loss of motivation) are also a top treatment priority for healthcare providers and consumers due to the profound impact these illness features have on self-care, daily routines, and interpersonal relationships (15).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders

et al. 2023

View full text Add to dashboard Cite

Leading professional health bodies have called for the wider adoption of Patient Reported Outcome Measures, such as quality of life, in research and clinical practice as a means for understanding why the global burden of depression continues to climb despite increased rates of treatment use. Here, we examined whether anhedonia -an often recalcitrant and impairing symptom of depression -along with its neural correlates, was associated with longitudinal changes in patient-reported quality of life among individuals seeking treatment for mood disorders. We recruited 112 participants, including n = 80 individuals with mood disorders (58 unipolar, 22 bipolar) and n = 32 healthy controls (63.4% female). We assessed anhedonia severity along with two electroencephalographic markers of neural reward responsiveness (scalp-level 'Reward Positivity' amplitude and source-localized reward-related activation in the dorsal anterior cingulate cortex), and assessed quality of life at baseline, 3-and 6-month follow-up. Anhedonia emerged as a robust correlate of quality of life cross-sectionally and longitudinally among individuals with mood disorders. Furthermore, increased neural reward responsiveness at baseline was associated with greater improvements in quality of life over time, and this improvement was mediated by longitudinal improvements in anhedonia severity. Finally, differences in quality of life observed between individuals with unipolar and bipolar mood disorders were mediated by differences in anhedonia severity. Our ndings indicate that anhedonia and its reward-related neural correlates are linked to variability in quality of life over time in individuals with mood disorders. Treatments capable of improving anhedonia and normalizing brain reward function may be necessary for improving broader health outcomes for individuals seeking treatment for depression.ClinicalTrials.gov identi er: NCT01976975

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Given the data currently available, there seems to be a bidirectional relationship between hypertension and obstructive sleep apnea syndrome (OSAS). Indeed, OSAS is a frequent comorbidity in hypertensive subjects and apneic subjects have a high prevalence of hypertension [ 1 , 2 ]. In addition, OSAS is a risk factor for hypertension whereas hypertension appears to predispose to the development of OSAS [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

10-Year Risk for Cardiovascular Disease Associated with COMISA (Co-Morbid Insomnia and Sleep Apnea) in Hypertensive Subjects

Draelants,

Point,

Wacquier

et al. 2023

Life

Self Cite

View full text Add to dashboard Cite

Due to the few studies available, this study aimed to investigate the 10-year risk for cardiovascular disease (CVD) associated with COMISA (co-morbid insomnia and sleep apnea) in hypertensive subjects. Clinical data of 1009 hypertensive subjects extracted from the Sleep Laboratory database were analyzed. Framingham Risk Score ≥ 10% was used as a cut-off to identify hypertensive subjects with high 10-year risk for CVD. The association between 10-year risk for CVD and COMISA was investigated using logistic regression analyses. 65.3% of hypertensive subjects from our sample presented a high 10-year risk for CVD. After controlling for major confounding factors, multivariate logistic regression analyses demonstrated that unlike its components present separately, COMISA was significantly associated with high 10-year risk for CVD in hypertensive subjects (OR 1.88, 95% CI 1.01–3.51). In this study, we have demonstrated that the negative synergy between obstructive sleep apnea syndrome and insomnia disorder seems to play a central role in the 10-year risk for CVD in hypertensive subjects, which seems to indicate that the establishment of a systematic research and an adapted treatment of COMISA could open new perspectives to promote a better cardiovascular outcome in this specific subgroup of patients.

show abstract

“…Likewise, hyperglycemia, diet-induced changes in insulin signaling, and knockout of insulin receptors facilitate depression and anhedonia-like behavior in rodents (Aswar et al, 2017;Dutheil et al, 2016;Horman et al, 2021;Kleinridders et al, 2015). However, we did not observe altered metabolic hormone concentrations in MDD compared to HCPs when adjusted for age, sex, and BMI; only higher glucose levels were found in MDD, supporting that primarily the anhedonic subtype of MDD is associated with metabolic dysregulation (Moreira et al, 2019;Willame et al, 2022). Although neither insulin sensitivity nor glucose levels affected food ratings, it is plausible that the effect is smaller if food is only tasted and not consumed ad libitum.…”

Section: Discussionmentioning

confidence: 46%

Blunted anticipation but not consummation of food rewards in depression

Schulz,

Klaus,

Peglow

et al. 2024

Preprint

View full text Add to dashboard Cite

Anhedonia is a core symptom of major depressive disorder (MDD) and is associated with worse treatment outcomes. While its narrow definition as a hedonic or consummatory deficit evolved to encompass anticipatory and motivational reward facets, it remains unclear where reward deficits manifest. Since evidence that metabolic hormones influence reward processing accumulates, investigating their role in alleviating reward deficits may provide crucial insights. To address these gaps, we conducted a study with 103 participants, including 52 patients with MDD and 51 healthy control participants (HCPs). After overnight fasting, blood samples were collected to determine the concentration of ghrelin, glucose, insulin, and triglycerides in serum/plasma. Participants then completed a taste test with repeated ratings of wanting and liking for snacks before and after tasting, allowing to gradually move from reward anticipation to consummation. Patients with MDD showed decreased wanting (p = .046) but not liking for food rewards during visual anticipation. However, these group differences disappeared once patients inspected and tasted the food as patients increased wanting relative to HCPs (p = .004), providing strong evidence against the hypothesis of a consummatory deficit (Bayes Factors > 9). In contrast to a narrow definition of anhedonia, higher scores on the Snaith-Hamilton Pleasure Scale (SHAPS) were more strongly associated with reduced anticipatory food wanting (p = .010), not liking, and more pronounced increases in wanting with reward proximity (p = .037). Across groups and phases, acyl ghrelin was associated with higher wanting and liking ratings, while poor glycemic control was associated with anhedonia. Overall, our study demonstrates that MDD and its cardinal symptom, anhedonia, are associated with a reduced anticipation of rewards rather than an impaired ability to experience pleasure. Since ghrelin was associated with elevated reward ratings, targeting the gut-brain axis could be a promising avenue for treating reward deficits.

show abstract

The association between type 2 diabetes and anhedonic subtype of major depression in hypertensive individuals

Cited by 11 publications

References 52 publications

Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders

Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders

10-Year Risk for Cardiovascular Disease Associated with COMISA (Co-Morbid Insomnia and Sleep Apnea) in Hypertensive Subjects

Blunted anticipation but not consummation of food rewards in depression

Contact Info

Product

Resources

About